Amitriptyline headache and sleep disorders in patients with mild stroke

Investigating the effectiveness of amitriptyline in preventing headache and sleep disorders in patients with mild brainstorming

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230627058603N1

Enrollment

110

Registered

2024-01-03

Start date

2023-08-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild brain trauma. Diffuse traumatic brain injury

Interventions

Intervention 1: Intervention group: Amitriptyline from Daropakhsh pharmaceutical company started with a dose of 10 mg and continued up to 50 mg, and according to the patient s tolerance, it was increa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient satisfaction to enter the study Patients with mild strokes with a consciousness coefficient of between 13-15

Exclusion criteria

Exclusion criteria: Patients with moderate and high brain trauma Patients with a history of any brain disorders Bipolar and family history Patients with long QT and arrhythmia history Seizure A history of headaches and mood disorders Incidence of any drug complications

Design outcomes

Primary

Measure	Time frame
Headache. Timepoint: 6 months after intervention. Method of measurement: HDI Standard Headache Questionnaire.;Sleep disorders. Timepoint: 6 months after intervention. Method of measurement: Pittsburgh's sleep quality questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Shafiei

Esfahan University of Medical Sciences

mui@mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026